Wockhardt’s antibiotic Zaynich has received approval from the US drug regulator, marking it as only the second Indian-developed drug to gain such nod. The drug targets complicated urinary tract infections (UTIs) and represents the fruition of the company’s $800-million investment in antibiotic research. The approval was announced on Saturday, highlighting a significant milestone for Wockhardt and its chairman Habil Khorakiwala, according to livemint.com.
The approval process for Zaynich culminated after years of dedicated research and development led by Wockhardt, which persisted with antibiotic discovery despite many global pharmaceutical companies shifting focus to more profitable drug categories. Habil Khorakiwala’s commitment to this niche was vindicated as the US Food and Drug Administration (FDA) granted the regulatory nod, enabling Wockhardt to commercialize the drug in the US market. This achievement underscores the company’s strategic bet on antibiotic innovation.
This approval is notable in the context of the global pharmaceutical industry, where antibiotic research has declined due to lower returns compared to other drug types. Wockhardt’s success with Zaynich positions it alongside only one other Indian drug to have secured US regulatory approval, setting a precedent for Indian pharmaceutical firms in the international arena. The development could influence other Indian companies to invest in antibiotic research, a field critical to addressing resistant infections worldwide.
Wockhardt now aims to capitalize on the US approval by launching Zaynich commercially, potentially expanding its footprint in the global antibiotics market. The company’s next steps include scaling production and distribution to meet US demand, with commercial activities expected to commence shortly following the regulatory clearance.